T

    Travere Therapeutics Inc (TVTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $66.28
    +0.61 (+0.93%)

    Market Cap: $6.19B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(24/40)
    Avg Surprise
    +193.89%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.51
    Range$-0.57 - $1.16
    8 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$0.55+7.2%
    60d ago$0.38-24.9%
    30d ago$0.40-22.7%
    7d ago$0.50-2.2%
    Current$0.51
    Revenue Consensus
    $195M
    Range$157M - $240M
    14 analysts
    Dec 31, 2026
    EPS Consensus$0.95
    Range$0.17 - $2.16
    8 analysts
    Revenue Consensus
    $233M
    Range$144M - $316M
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.95---
    Sep 26EST
    		-$0.51---
    Jun 26
    		$-0.37$-0.14-164.29%Miss-384.6%
    Mar 26
    		$0.05$-0.06+183.33%Beat+126.3%
    Dec 25
    		$0.37$-0.04+1025.00%Beat+178.7%
    Sep 25
    		$0.59$-0.08+837.50%Beat+228.3%
    Jun 25
    		$0.13$0.04+225.00%Beat+120.0%
    Mar 25
    		$-0.19N/A+51.28%Beat+87.4%
    Dec 24
    		$-0.47$-0.38-24.14%Miss+50.0%
    Sep 24
    		$-0.46$-0.54+14.81%Beat-120.3%
    Jun 24
    		$-0.65$-0.72+9.72%Beat+15.6%
    Mar 24
    		$-1.51$-0.79-91.14%Miss-84.1%
    Dec 23
    		$-0.94$-0.92-2.17%Miss+8.7%
    Sep 23
    		$2.27$0.04+5575.00%Beat+398.7%
    Jun 23
    		$-0.77$-0.93+17.20%Beat-18.5%
    Mar 23
    		$-0.82$-1.03+20.39%Beat+0.0%
    Dec 22
    		$-1.03$-1.07+3.74%Beat-68.9%
    Sep 22
    		$-0.76$-0.70-8.57%Miss-484.6%
    Jun 22
    		$-0.65$-0.70+7.14%Beat-66.7%
    Mar 22
    		$-0.82$-0.73-12.33%Miss-49.1%
    Dec 21
    		$-0.61$-0.50-22.00%Miss-27.1%
    Sep 21
    		$-0.13N/A+72.92%Beat-18.2%
    Jun 21
    		$-0.39$-0.50+22.00%Beat-77.3%
    Mar 21
    		$-0.55$-0.30-83.33%Miss-175.0%
    Dec 20
    		$-0.48$-0.47-2.13%Miss-84.6%
    Sep 20
    		$-0.11N/A+62.07%Beat+83.3%
    Jun 20
    		$-0.22$-0.36+38.89%Beat+62.1%
    Mar 20
    		$-0.20N/A+61.54%Beat+68.3%
    Dec 19
    		$-0.26$-0.37+29.73%Beat-44.4%
    Sep 19
    		$-0.66$-0.60-10.00%Miss+2.9%
    Jun 19
    		$-0.58$-0.40-45.00%Miss-132.0%
    Mar 19
    		$-0.63$-0.36-75.00%Miss-350.0%
    Dec 18
    		$-0.18N/A+62.50%Beat+60.0%
    Sep 18
    		$-0.68$-0.26-161.54%Miss-553.3%
    Jun 18
    		$-0.25$-0.11-127.27%Miss-933.3%
    Mar 18
    		$-0.14N/A+61.11%Beat-1500.0%
    Dec 17
    		$-0.45$-0.19-136.84%Miss-95.7%
    Sep 17
    		$0.15$-0.04+475.00%Beat+266.7%
    Jun 17
    		$0.03$0.03+0.00%Beat-
    Mar 17
    		$0.01N/A+103.85%Beat-
    Dec 16
    		$-0.23$-0.26+11.54%Beat-
    Sep 16
    		$-0.09$0.06-250.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio103.56EV/EBITDA1123.81x
    Price/FCF211.17xFCF Yield0.47%
    Profitability
    Profit Margin-7.35%Operating Margin2.33%
    ROE-236.40%ROIC-5.46%
    Financial Health
    Debt/Equity24.83xInterest Coverage-3.65x
    Current Ratio4.05xQuick Ratio3.99x
    Trading Statistics
    Beta1.04Avg Volume1.68M
    52-Week High$67.8552-Week Low$17.27

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$65.89
    SMA 20$63.59
    SMA 50$59.52
    SMA 200$41.79
    EMA 10$65.52
    EMA 20$63.67
    EMA 50$59.06
    EMA 200$44.38

    MACD

    Line: 2.47Signal: 2.40Hist: 0.07

    ADX

    ADX: 35.2+DI: 26.5-DI: 12.1

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down20.0
    PSAR$60.19

    Bollinger Bands

    Upper Band$69.33
    Lower Band$57.84
    %B Position1807%(Upper)
    Band Width0.73

    RSI (14-Day)

    Neutral
    63.3

    Momentum Oscillators

    Stoch %K82.0
    Stoch %D88.2
    Williams %R-21.1
    ROC (10d)4.3%
    Momentum2.75
    CCI (20d)79.2
    MFI (14d)59.0

    Volatility Measures

    ATR (14d)$2.38(3.6%)
    StdDev (20d)2.87
    Hist Vol50.1%(High)

    Volume Flow

    VWAP$66.02
    OBV19.5M
    AD Line60.8M
    CMF (20d)0.006

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol Ratio1.1x
    VWMA (20d)$63.12

    Pivot Points

    R3$69.04
    R2$68.24
    R1$66.96
    Pivot Point$66.16
    S1$64.88
    S2$64.08
    S3$62.80

    Advanced Oscillators

    TSI31.07
    Ultimate Osc65.9
    KST138.50

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$169.58M$127.20M$129.69M$164.86M$114.45M$81.73M$74.79M$62.90M$54.12M$41.37M$45.06M$37.09M
    Cost of Revenue$2.17M$26.77M$2.55M$1.58M$1.52M$4.68M$2.55M$1.63M$12.41M$1.50M$16.42M$1.29M
    Gross Profit$167.41M$100.43M$127.14M$163.27M$112.93M$77.05M$72.23M$61.27M$41.71M$39.87M$28.64M$35.81M
    Operating Expenses$163.46M$137.35M$159.56M$138.34M$125.58M$119.73M$132.97M$117.42M$108.76M$179.11M$111.48M$128.39M
    R&D$60.28M$57.09M$57.87M$51.89M$49.36M$46.89M$62.07M$51.68M$54.33M$114.63M$58.75M$60.59M
    SG&A$96.11M$80.25M$101.69M$86.45M$76.22M$72.84M$69.50M$65.62M$64.78M$64.22M$63.59M$67.80M
    Operating Income$3.95M$-36,915,000$-32,428,000$24.93M$-12,650,000$-42,674,000$-60,737,000$-56,149,000$-67,051,000$-139,237,000$-82,839,000$-92,585,000
    Interest Income$3.36M$2.58M$2.59M$3.05M$3.29M$3.79M$3.79M$3.57M$4.42M$6.03M$7.15M$5.84M
    Interest Expense$2.13M$2.30M$2.30M$2.75M$2.85M$2.86M$2.82M$2.78M$2.79M$2.80M$2.82M$2.82M
    Income Before Tax$-35,001,000$-36,722,000$-21,065,000$25.71M$-12,735,000$-41,187,000$-60,340,000$-54,836,000$-69,567,000$-135,767,000$-88,528,000$-89,229,000
    Income Tax Expense$-204,000$-120,000$921,000$8,000$20,000$39,000$-72,000$-84,000$85,000$191,000$68,000$12,000
    Net Income$-34,797,000$-37,102,000$2.73M$25.71M$-12,755,000$-41,226,000$-60,264,000$-54,811,000$-70,409,000$-136,061,000$-90,173,000$150.74M
    EBITDA$-32,867,000$-9,210,000$-632,000$44.25M$4.13M$-25,528,000$-45,430,000$-40,820,000$-56,434,000$-123,087,000$-73,855,000$-74,933,000
    EBITN/A$-34,422,000$-18,769,000$28.46M$-9,889,000$-38,330,000$-57,523,000$-52,059,000$-66,779,000$-132,967,000$-85,707,000$-86,408,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TVTX

    Government Contracts

    Gov Obligations (TTM)
    $337025
    Gov Obligations / Revenue
    0.1%
    Obligations YoY
    N/A
    Active Awards
    9
    New Awards (TTM)
    9
    Avg Remaining Term
    6.2 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26226N0373Department of Veterans AffairsDepartment of Veterans Affairs$131523Feb 10, 2026
    36C24526N0779Department of Veterans AffairsDepartment of Veterans Affairs$33372Jul 30, 2026
    36C24526N0571Department of Veterans AffairsDepartment of Veterans Affairs$33372May 7, 2026
    36C24526N0284Department of Veterans AffairsDepartment of Veterans Affairs$31408Jan 29, 2026
    36C24526N0130Department of Veterans AffairsDepartment of Veterans Affairs$28975Nov 5, 2025
    36C24525N0858Department of Veterans AffairsDepartment of Veterans Affairs$28975Aug 1, 2025
    36C24526N0554Department of Veterans AffairsDepartment of Veterans Affairs$17667Apr 29, 2026
    36C24526N0725Department of Veterans AffairsDepartment of Veterans Affairs$15867Jul 10, 2026
    36C24526N0675Department of Veterans AffairsDepartment of Veterans Affairs$15867Jun 24, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Travere Therapeutics stock hits 52-week high at 66.35 USD

    Travere Therapeutics (TVTX) stock reached a new 52-week high of $66.35, capping a significant rally with a 112% gain over six months and a 69% year-to-date return. This surge is fueled by strong Q2 2026 financial results, including revenue surpassing forecasts and a near doubling in sales for their kidney drug, FILSPARI. Despite trading above its InvestingPro Fair Value, analysts maintain price targets between $62 and $90, with Stifel raising its target to $62 due to FILSPARI's exceptional performance.

    Investing.com•8/22/26•
    Bullish

    Travere Therapeutics stock hits 52-week high at 66.35 USD By Investing.com

    Travere Therapeutics Inc (TVTX) stock reached a new 52-week high of $66.35, trading within 1% of this peak. This comes after the company reported strong Q2 2026 financial results, with revenue of $169.6 million, largely driven by the kidney drug FILSPARI, whose sales nearly doubled year-over-year. Stifel also raised its price target for Travere Therapeutics to $62, citing FILSPARI's exceptional performance following its FSGS launch.

    Investing.com South Africa•8/21/26•
    Bullish

    Travere Therapeutics stock hits 52-week high at 66.35 USD By Investing.com

    Travere Therapeutics (TVTX) stock reached a new 52-week high of $66.35, reflecting a 112% gain over six months and a 265.46% increase over the past year. This surge is largely driven by the strong performance of their kidney drug, FILSPARI, which helped the company exceed revenue forecasts in Q2 2026. Despite being considered overvalued by some analyses, analysts maintain price targets ranging from $62 to $90.

    Investing.com South Africa•8/21/26•
    Bullish

    Travere Therapeutics (TVTX) Is Up 6.1% After FILSPARI Beats FSGS Launch Expectations

    Travere Therapeutics (TVTX) saw its stock rise by 6.1% after its drug FILSPARI exceeded launch expectations for FSGS treatment, demonstrating broad physician demand among over 30,000 U.S. patients. The company is also advancing its rare disease pipeline with pegtibatinase for classical homocystinuria and civorebrutinib for multiple renal indications. This strong performance in FSGS is expected to reshape Travere's investment narrative, which is heavily focused on its kidney portfolio, and has led to a potential upside in its fair value estimates.

    Sahm•8/21/26•
    Bullish

    Travere Therapeutics (TVTX) Is Up 6.1% After FILSPARI Beats FSGS Launch Expectations

    Travere Therapeutics (TVTX) saw its stock rise by 6.1% following news that its drug FILSPARI's launch for FSGS is exceeding expectations, driven by strong physician demand. This success reinforces the company's kidney-focused portfolio, which also includes a Phase III trial for pegtibatinase and the addition of civorebrutinib to its pipeline. While the strong launch boosts near-term growth, the article also notes the ongoing risk of heavy reliance on FILSPARI and increasing competition in the kidney disease market.

    Simply Wall Street•8/20/26•
    Bullish

    Frequently Asked Questions About TVTX

    Does TVTX pay dividends?
    Travere Therapeutics Inc (TVTX) does not currently pay a regular dividend.
    What is TVTX's P/E ratio?
    Travere Therapeutics Inc has a price-to-earnings (P/E) ratio of 103.56.
    What is TVTX's market cap?
    Travere Therapeutics Inc (TVTX) has a market capitalization of $6.19B with a current stock price of $66.28.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In